Further comparative trial of triethylene thiophosphoramide and mechlorethamine in patients with Melanoma and Hodgkin's disease
| Autor: | K.Gale Potee, Bruce I. Shnider, Barbara Lipowska, Leonard G. Salvin, Jacob Colsky, Clyde O. Brindley, William Regelson |
|---|---|
| Rok vydání: | 1964 |
| Předmět: |
Drug
medicine.medical_specialty Epidemiology media_common.quotation_subject medicine.medical_treatment New York Disease Toxicology Gastroenterology Internal medicine medicine In patient Mechlorethamine Melanoma Thiophosphoramide media_common Chemotherapy business.industry Comparative trial medicine.disease Hodgkin Disease Surgery District of Columbia Toxicity business Thiotepa |
| Zdroj: | Journal of Chronic Diseases. 17:19-30 |
| ISSN: | 0021-9681 |
| DOI: | 10.1016/0021-9681(64)90036-0 |
| Popis: | A comparative trial was carried out by the Eastern Cooperative Group in Solid Tumor Chemotherapy in 49 patients with melanoma and 48 patients with Hodgkin's disease with the two alkylating agents methyl-bis (β-chloroethyl)amine hydrochloride (HN 2 ) and triethylene thiophosphoramide (TSPA). In patients with melanoma the response rate was 12.5 per cent for 4–29 months with TSPA and zero in the comparable group treated by HN 2 . In Hodgkin's disease the drugs were given at two dose levels, one near the maximum tolerated dose and the other at one-half of this. At the higher dose level significant tumor reduction occurred in 50 per cent of the patients for a median of 44 days with HN 2 and in 59.1 per cent of patients for a median of 36 days with TSPA. These results are not significantly different and suggest that at equal toxicity the drugs have similar antitumor effects in patients with Hodgkin's disease. At the low dose level the response rate with TSPA was only 11.1 per cent. A statistically significant difference was found between the response rate with low and with high doses of TSPA. Too few cases were studied to draw conclusions referable to HN 2 in regard to optimal dose for this drug. Evidence was obtained that for the alkylating agent TSPA the antitumor effects in patients with Hodgkin's disease are dose dependent and that there is a relationship between degree of toxicity and antitumor effects. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|